Navigation Links
diaDexus, Inc. Pre-Announces 2011 Q4, YE Revenue and 2012 Guidance
Date:1/9/2012

SOUTH SAN FRANCISCO, Calif., Jan. 9, 2012 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS.OB), a diagnostics company focused on patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced preliminary Q4 2011 revenues of approximately $4.9 million, up 48% from the prior year's fourth quarter. This result brings projected year-end 2011 revenue to $16.4 million, up 39% over 2010's full year revenues. These preliminary results are unaudited and subject to adjustment prior to the Company filing its Annual Report on Form 10-K on or before March 21, 2012.

The Company also announced a preliminary cash and investments balance of approximately $17.2 million as of December 31, 2011. This preliminary balance is unaudited and subject to adjustment prior to the Company filing its Form 10-K on or before March 21, 2012.

diaDexus provided new guidance for 2012 total revenue at $20 - 21 million, estimating year-over-year growth of approximately 26% compared to 2011.

According to Brian E. Ward, Ph.D, Chief Executive Officer, "2011's strong revenue growth reflects significant assay purchases by cardiovascular specialty laboratories. diaDexus' dominant role as the only supplier of LP-PLA2 assays in this market, plus  the fact that the PLAC Test has become a cornerstone of comprehensive diagnostic lipid profile analysis,  are the primary contributors to this growth. We also believe that guidelines published in 2010 and 2011 by the American Heart Association and the American Stroke Association to support testing of LP-PLA2, coupled with emerging clinical utility data, are increasing physician awareness of this important cardiovascular risk assessment tool. Looking forward, we believe this growth trend will continue to be fueled by penetration of more generalized laboratories, our new activity assay which will be launched in Europe, broader reimbursement coverage, and additional positive clinical outcomes data."

The company expects to report 2011 year-end financial results on or around March 21, 2012.

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. For more information, please visit the company's website at www.diaDexus.com

Forward-Looking Statements 

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products and other statements that are not historical in nature, particularly those that use terminology such as "will," "potential", "could," "can," "believe," "intends," "continue," "plans," "expects," "estimates" or comparable terminology. Forward-looking statements are based on current expectations and assumptions, and entail various known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to diaDexus that could cause actual results to differ materially from those expressed in such forward-looking statements include diaDexus' ability to maintain regulatory clearance for and successfully commercialize its PLAC test, including its ability to submit a new 510(k) application for, and obtain FDA clearance of, its new automated Lp-PLA2 activity assay; its ability to hire a chief financial officer and to attract, retain and motivate other qualified personnel: its relationship with key customers; diaDexus' reliance on sole source third party manufacturers to manufacture and supply diaDexus' main reagent and the PLAC Test; the effects of government regulations and the company's ability to comply with such regulations; diaDexus' ability to demonstrate that treatment of individuals based on their Lp-PLA2 levels improves clinical outcomes in prospective clinical studies; the rate of adoption of the PLAC Test by doctors and laboratories; third party payors' acceptance of and reimbursement for the PLAC Test; downward pressure on diaDexus' product pricing, particularly from the company's largest customers; the adequacy of the company's intellectual property rights; diaDexus' limited revenue and cash resources; diaDexus' ability to accurately forecast revenues prior to review and issuance of its financial statements for the year ending December 31, 2011; and diaDexus' significant corporate expenses, including real estate liabilities and expenses associated with being a public company. Additional factors that could cause diaDexus' results to differ materially from those described in the forward-looking statements can be found in diaDexus' most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and diaDexus disclaims any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
2. diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter
3. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
4. RSB Spine, LLC Announces 2011 Revenue Growth
5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
6. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
7. Neogen Reports First Quarter Revenue and Net Income Increases
8. Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010
9. Cord Blood America Six Month Revenues Up 61 Percent; Gross Profit Up 100 Percent
10. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
11. NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the launch of ... on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO Summit ... peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a unique set ...
(Date:3/22/2017)... Milwaukee, WI (PRWEB) , ... March 22, 2017 , ... ... federal scientific research agencies as outlined in the Administration’s recently published fiscal year 2018 ... for the National Institutes of Health (NIH) by $5.8 billion or roughly 20% of ...
(Date:3/22/2017)... , March 22, 2017  Personal Genome ... its cancer testing contract with the U.S. Department ... tumor profiling assay with the company,s new CancerSELECT ... comprehensive, clinically actionable pan-cancer profiling test that includes ... assess potential patient response to checkpoint inhibitor immunotherapies. ...
(Date:3/20/2017)... ... , ... SSCI and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, are ... the Parenteral Drug Association (PDA), the New York Interphex Show will open on March ... more than 625 exhibitors, the educational and networking opportunities are extremely valuable. INTERPHEX is ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the leading ... The Prince,s Trust to uncover insights to support its ... Trust. The UK,s leading youth charity will be using ... results and get a better understanding of the topics and issues ... ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
Breaking Biology News(10 mins):